美国妊娠期肝内胆汁淤积症患者死产风险研究
该回顾性队列研究利用2015-2020年美国全国再入院数据库,分析妊娠期肝内胆汁淤积症(ICP)与死产风险的关系。共识别9,987,705例分娩住院,其中152,040例(0.8%)有ICP诊断。ICP患者死产率低于无ICP者(每10万分娩252 vs 386),调整后风险差为每10万分娩减少160例死产(95%CI 127-194),且ICP患者更易早产(30.1% vs 9.3%,P<.001)。
要点
- ICP患者死产率低于无ICP者(每10万分娩252 vs 386),调整混杂后仍较低。
- ICP患者早产率高于无ICP者(30.1% vs 9.3%,P<.001)。
- 按分娩孕周分层后,未观察到ICP患者死产率升高。
核心结论
- 有ICP诊断编码的患者比无ICP诊断编码者分娩更早,但死产百分比更低,即使按出生孕周分层也是如此。
- 这些结果可能让被诊断为ICP的患者放心,当前管理确实降低了ICP的死产风险。
研究设计与样本
- 回顾性队列研究,使用2015-2020年美国全国再入院数据库(由美国医疗保健研究与质量局开发的行政数据库)。
- 通过国际疾病分类诊断和操作代码识别分娩住院、分娩孕周、ICP和死产的发生以及合并症。
- 比较有ICP与无ICP的孕妇在分娩住院时的分娩时机和死产率。
- 共识别9,987,705例分娩住院,对应加权全国估计18,609,207例出生;其中152,040例(0.8%)有ICP诊断。
主要发现
- ICP患者死产总体率低于无ICP者(每10万分娩252 vs 386;风险差为每10万分娩减少133例;95%CI 98-170)。
- 调整保险状态、社会经济因素和合并症后,风险差为每10万分娩减少160例死产(95%CI 127-194)。
- ICP患者早产比例高于无ICP者(30.1% vs 9.3%;P<.001)。
- 按分娩孕周分层后,未观察到ICP患者在任何时间点死产率升高。
- ICP患者年龄更大,合并症有小差异,如妊娠期糖尿病率高于无ICP者。
临床怎么用
- 原文结论认为当前管理确实降低了ICP的死产风险,可能让被诊断为ICP的患者放心。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Intrahepatic cholestasis of pregnancy is associated with a 4- to 10-fold increase in the risk of stillbirth in the absence of intervention, leading to recommendations for antenatal assessment, ursodiol use, and often preterm or early term delivery. OBJECTIVE: This study aimed to determine whether current management strategies for intrahepatic cholestasis of pregnancy mitigate the elevated risk of stillbirth at a population level. STUDY DESIGN: This was a retrospective cohort study using the 2015-2020 National Readmissions Database, an administrative database developed by the United States Agency for Healthcare Research and Quality. Our study identified delivery hospitalizations, gestational age at delivery, occurrence of intrahepatic cholestasis of pregnancy and stillbirth, and comorbid conditions using the International Classification of Diseases diagnosis and procedure codes. Moreover, this study compared the timing of delivery and stillbirth rates of pregnant patients with intrahepatic cholestasis of pregnancy vs those without intrahepatic cholestasis of pregnancy at the time of delivery hospitalization. RESULTS: This study identified a cohort of 9,987,705 delivery hospitalizations in the National Readmissions Database, corresponding to a weighted national estimate of 18,609,207 births. Of these births, 152,040 (0.8%) were noted to have an intrahepatic cholestasis of pregnancy diagnosis. Patients with an intrahepatic cholestasis of pregnancy diagnosis were older, with small differences in comorbidities, such as a higher rate of gestational diabetes mellitus, than patients without an intrahepatic cholestasis of pregnancy diagnosis at delivery hospitalization. The overall rates of stillbirth were lower among those with intrahepatic cholestasis of pregnancy than among those without intrahepatic cholestasis of pregnancy (252 vs 386 per 100,000 deliveries; risk difference, 133 fewer per 100,000 deliveries; 95% confidence interval, 98-170), a finding that persisted after adjustment for insurance status, socioeconomic factors, and comorbid conditions (risk difference, 160 fewer stillbirths per 100,000 deliveries; 95% confidence interval, 127-194). Furthermore, although patients with intrahepatic cholestasis of pregnancy were more likely to deliver before term than those without intrahepatic cholestasis of pregnancy (30.1% vs 9.3%; P<.001), increased rates of stillbirth were not noted at any point after stratification of the cohort by gestational age at delivery. CONCLUSION: Patients with intrahepatic cholestasis of pregnancy diagnosis codes delivered earlier than those without intrahepatic cholestasis of pregnancy diagnosis codes, but the percentage of births affected by stillbirth was lower, even when stratifying for gestational age at birth. These results may provide reassurance to patients receiving an intrahepatic cholestasis of pregnancy diagnosis that current management does mitigate stillbirth risk in intrahepatic cholestasis of pregnancy.
引用
- Estin ML, Campbell AIK, Watkins VY, et al. Risk of stillbirth in United States patients with diagnosed intrahepatic cholestasis of pregnancy. Am J Obstet Gynecol. 2023. PMID: 37348778. doi:10.1016/j.ajog.2023.06.036
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。